Abbott Laboratories (ABT)

Abbott Laboratories Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	5,104	8,522	7,616	6,896	9,882	9,799
Short-Term Investments	499	417	351	383	288	450
Cash & Short-Term Investments	5,603	8,939	7,967	7,279	10,170	10,249
Cash Growth	-23.06%	12.20%	9.45%	-28.43%	-0.77%	43.38%
Accounts Receivable	8,599	7,929	6,925	6,565	6,218	6,487
Inventory	7,315	6,488	6,194	6,570	6,173	5,157
Other Current Assets	3,000	2,640	2,570	2,256	2,663	2,346
Total Current Assets	24,517	25,996	23,656	22,670	25,224	24,239
Net Property, Plant & Equipment	12,812	11,816	10,658	10,154	9,162	8,959
Other Intangible Assets	17,211	5,526	6,647	8,815	10,454	12,739
Goodwill	35,244	24,035	23,108	23,679	22,799	23,231
Long-Term Investments	1,111	918	886	799	766	816
Other Long-Term Assets	18,320	18,422	16,459	7,097	6,033	5,212
Total Assets	109,215	86,713	81,414	73,214	74,438	75,196

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4,794	4,240	4,195	4,295	4,607	4,408
Accrued Expenses	8,511	7,557	6,844	7,019	7,401	6,806
Current Portion of Long-Term Debt	3,005	3,033	1,500	1,080	2,251	754
Other Current Liabilities	1,504	1,666	1,618	1,447	1,230	1,137
Total Current Liabilities	17,814	16,496	14,157	13,841	15,489	13,105
Long-Term Debt	29,603	9,896	12,625	13,599	14,522	17,296
Other Long-Term Liabilities	10,036	7,550	6,731	6,947	7,522	8,771
Total Long-Term Liabilities	39,639	17,446	19,356	20,546	22,044	26,067
Total Liabilities	57,453	33,942	33,513	34,387	37,533	39,172

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	25,495	25,527	25,153	24,869	24,709	24,470
Treasury Stock	-17,967	-17,177	-16,844	-15,981	-15,229	-11,822
Accumulated Other Comprehensive Income	-6,212	-6,001	-7,906	-7,839	-8,051	-8,374
Retained Earnings	49,794	49,781	47,261	37,554	35,257	31,528
Total Common Shareholders' Equity	102,872	52,130	47,664	38,603	36,686	35,802
Minority Interest	652	641	237	224	219	222
Shareholders' Equity	103,524	52,771	47,901	38,827	36,905	36,024
Total Liabilities & Equity	109,215	86,713	81,414	73,214	74,438	75,196

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	32,608	12,929	14,125	14,679	16,773	18,050
Net Cash (Debt)	-27,005	-3,990	-6,158	-7,400	-6,603	-7,801
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-15.46	-2.28	-3.52	-4.23	-3.74	-4.36
Book Value	102,872	52,130	47,664	38,603	36,686	35,802
Book Value Per Share	58.90	29.82	27.27	22.07	20.80	20.01
Tangible Book Value	50,417	22,569	17,909	6,109	3,433	-168
Tangible Book Value Per Share	28.87	12.91	10.25	3.49	1.95	-0.09

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Jul 28, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error